A Test For Each Stage

The treatment of HIV is difficult for individuals who live with complex treatment regimens, side effects, and drug resistance. It is also a challenge for healthcare providers who work to make sure their patients are getting the right drugs, finding ways to cope with side effects, and most importantly, staying healthy.

Monogram Biosciences, Inc. is the leading provider of HIV tests that help manage the complexities of antiretroviral therapy. PhenoSense GT®, PhenoSense® and GeneSeq®, have for many years helped healthcare providers choose the drugs that will provide the greatest benefit to individual patients. More recently PhenoSense Entry and PhenoSense Integrase have been added, mirroring the increased breadth of classes of HIV drugs.

PhenoSenseGT®

PhenoSenseGT combines phenotype and genotype drug resistance results in a single report. PhenoSenseGT also includes a measure of replication capacity (RC), sometimes called viral fitness and HIV-1 subtype.

Choosing PhenoSenseGT after 2 regimen failures allows healthcare providers to retain options in patients' drug-regimen strategy that may preserve drug choices for a later time. While sophisticated in its technology, PhenoSenseGT remains user-friendly. The report form includes updated upper and lower clinical cutoffs and a summary page.

Even in complex cases, PhenoSenseGT brings clarity to healthcare providers' treatment choices. Both phenotypic and genotypic results come from the same blood sample, so it is possible to resolve disagreement between them. This comprehensive test gives healthcare providers advanced, practical insight into viral susceptibility.

PhenoSense®

PhenoSense offered as a single HIV drug resistance test or in the combination test, PhenoSenseGT, represents cutting-edge resistance testing technology. PhenoSense provides the most accurate quantitative measurement of susceptibility to individual drugs. PhenoSense drug resistance results are provided with a measure of viral fitness or Replication Capacity (RC).

The PhenoSense report form includes drug resistance information for all of the approved nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs).

GeneSeq®

GeneSeq is a highly accurate genotypic HIV drug resistance test. The test is performed using state-of-the-art technology and the results are determined using the most recently updated HIV mutation information and information from scientific research and Monogram Biosciences' resistance experts.

The GeneSeq report form includes drug resistance information for all of the approved nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors (PIs).

Replication Capacity (RC)

Replication Capacity measures how well a patient's virus is able to replicate compared to a wild-type reference virus. Although drug resistance mutations enable viruses to replicate in the presence of a drug, they may do so at some fitness cost to the viruses. Understanding how fit a patient's virus is may provide insight in a highly complex case; Replication capacity can help make decisions about when to delay, start, stop, switch or interrupt therapy. Replication Capacity is included with PhenoSenseGT, PhenoSense, and PhenoSense Integrase.

Isentress® is a registered trademark of Merck & Co., Inc.